Overview

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Status:
Not yet recruiting

Trial end date:
2037-12-01

Target enrollment:

Participant gender:

Summary

This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

Phase:

Phase 2

Details

Lead Sponsor:

John Lister

Collaborators:

AHN Cancer Institute
Lentigen Technology, Inc.
Miltenyi Biotec GbmH